These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Eruptive nevi after injection of drugs marketed as melanotan II. The first two Swedish cases described]. Burian E; Burian E Lakartidningen; 2013 Jan 30-Feb 5; 110(5):208-10. PubMed ID: 23451671 [No Abstract] [Full Text] [Related]
6. Eruptive naevi and darkening of pre-existing naevi 24 h after a single mono-dose injection of melanotan II. Schulze F; Erdmann H; Hardkop LH; Anemüller W; Rose C; Zillikens D; Fischer TW Eur J Dermatol; 2014; 24(1):107-9. PubMed ID: 24334249 [No Abstract] [Full Text] [Related]
16. Consider underlying body dysmorphic disorder in users of melanotan. Affleck A Br J Dermatol; 2010 Feb; 162(2):459-60. PubMed ID: 19919633 [No Abstract] [Full Text] [Related]
17. Use of melanotan I and II in the general population. Evans-Brown M; Dawson RT; Chandler M; McVeigh J BMJ; 2009 Feb; 338():b566. PubMed ID: 19224885 [No Abstract] [Full Text] [Related]
19. Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues: a review. Habbema L; Halk AB; Neumann M; Bergman W Int J Dermatol; 2017 Oct; 56(10):975-980. PubMed ID: 28266027 [TBL] [Abstract][Full Text] [Related]
20. Eruptive melanocytic nevi with satellite lesions following insulin treatment in a girl with type 1 diabetes mellitus. Kim DH; Lee JS; Koo DW; Jung KE J Dermatol; 2015 May; 42(5):547-8. PubMed ID: 25766430 [No Abstract] [Full Text] [Related] [Next] [New Search]